LL-37 dosage chart
This summary table compares available dose amounts and schedules by administration route.
| Route | Dose | Frequency & duration |
|---|---|---|
| Topical | 0.5 or 1.6 mg/mL | Twice weekly · 13 weeks |
| Injectable | 500 mcg–1.6 mg | 1-2 times daily · 2-4 weeks |
LL-37 dosage by administration route
LL-37 topical dosage
Topical venous-ulcer protocols use 0.5 or 1.6 mg/mL LL-37 solution twice weekly for 13 weeks. An application volume of 25 microliters per cm² of ulcer gives 12.5 or 40 mcg/cm², respectively, alongside wound dressings and compression care.[1]
LL-37 is a cathelicidin peptide involved in antimicrobial defense and barrier signaling. Local wound formulations target a different exposure pattern from systemic injections.[2][3][4][5]
LL-37 injectable dosage
Reported injectable protocols use 500 mcg–1.6 mg per administration, 1-2 times daily for 2-4 weeks. An additional reported subcutaneous range is 100–300 mcg once daily for 2–4 weeks. This is lower than the other reported injectable range above and is not a dose-equivalence rule for topical wound products.[6][3][2][8]
LL-37 is a cathelicidin peptide involved in antimicrobial defense and barrier signaling. Local wound formulations target a different exposure pattern from systemic injections.[6][7][4][5][3]
Frequency and timing
Use injections in the morning or evening. Apply topical products during dressing changes.[2]
LL-37 dosage calculator
Convert your chosen LL-37 amount into volume and U-100 syringe units. Adjust the inputs to match your vial and preparation.
LL-37 safety and side effects
Side effects and long-term safety
Topical use is the clearest local-tolerance context. Injectable LL-37 lacks a mature human pharmacokinetic and long-term systemic safety base. Topical LL-37 safety centers on local irritation and wound-care context. Injectable or systemic exposure is a different risk category, with added immune-activation, sterility, product-quality, and unknown exposure concerns.[2][6][7]
Route-specific dosing limits
Immune-active peptides need extra caution when infection, autoimmune disease, or open wounds are involved. Additional schedules attributed to Everything Peptide are reported patterns; citing research does not make these schedules clinically established or approved product instructions.[5][3][8]
Common LL-37 dosage questions
Can LL-37 doses be transferred between routes?
What dosage is listed for LL-37?
Topical venous-ulcer protocols use 0.5 or 1.6 mg/mL LL-37 solution twice weekly for 13 weeks.[1]
